Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

@article{Linardou2008AssessmentOS,
  title={Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.},
  author={Helena Linardou and Issa J. Dahabreh and Dimitra Kanaloupiti and Fotios Siannis and Dimitrios I Bafaloukos and Paris A. Kosmidis and Christos Papadimitriou and Samuel S. Murray},
  journal={The Lancet. Oncology},
  year={2008},
  volume={9 10},
  pages={962-72}
}
BACKGROUND Somatic mutations of the k-RAS oncogene have been assessed as a mechanism of de-novo resistance to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibition in patients with non-small-cell lung cancer (NSCLC), and to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer (mCRC). The aim of this systematic review and meta-analysis was to assess if k-RAS mutations represent a candidate predictive biomarker for anti-EGFR-targeted therapeutic strategies in… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 320 extracted citations

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology • 2010
View 9 Excerpts
Highly Influenced

Pharmacodynamic biomarkers: falling short of the mark?

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…